7/21/2019 Toradol

http://slidepdf.com/reader/full/toradol 1/2

DANIELLE B. QUIGAO

BSN IV-A GROUP II

Generic Name: Ketorolac

Brand Name: Toradol

Classificai!n: Nonsteroidal Anti-inflammatory Agents, Nonopioid Analagesics

"ec#anism !f Aci!n:

- Inhibits prostaglandin synthesis, producing peripherally mediated analgesia.

- Also has antipyretic and anti-inflammatory properties.

$#era%e&ic effec: Decreased pain

D!sa'e( R!&e( and )re*&enc+

A. Adults

1. Oral

Transfer to oral !" mg #O as first dose for patients $ho recei%ed &" mg I' or (" mg I) as a

single dose or (" mg multiple dose, follo$ed by 1" mg e%ery four to si* hours+ do not e*ceed "

mg! hr.

!. Ophthalmic

•  Acular / 1 drop 0id prn for stinging and burning+ use this drug up to ( days after

surgery.

• Itching due to allergic conuncti%itis 1 drop 0id

•   Acular, Acular #2 2or cataract surgery, begin by 1 drop 0id ! hours after and continue

for t$o $ee3s.

(. #arenteral

•  /ingle dose treatment &" mg I' or (" mg I)

•   'ultiple dose treatment (" mg I' or I) e%ery si* hours to a ma*imum 1!" mgday.

4. 5eriatric patients &6 years old and abo%e, patients $ho $eigh less than 6" 3g, and patients

$ith renal impairment

1. Oral

Transfer to oral 1" mg #O as first dose for patients $ho recei%ed (" mg I' or 16 mg I)

single dose or 16 mg I) or I' in multiple dose, then 1" mg #O e%ery four to si* hours+ do not

e*ceed using this drug " mg! hr.

!. #arenteral

• /ingle dose treatment (" mg I' or 16 mg I)

• 'ultiple dose treatment 16 mg I' or I) e%ery si* hours to a ma*imum of &" mgday

7. #ediatric patients Ketorolac8s safety and efficiency are not yet pro%en.

7/21/2019 Toradol

http://slidepdf.com/reader/full/toradol 2/2

Indicai!n:

/hort term management of pain 9not to e*ceed 6 days total for all routes combined:

C!nraindicai!ns and Ca&i!ns:

1. This drug should be use cautiously $ith patients $ho ha%e impaired hearing, allergies,

and cardio%asculargastrointestinalhepatic conditions.

!. It is contraindicated during labor and deli%ery and mothers $ho gi%es breastfeeding totheir baby.

(. 7ontraindicated to patients $ho $ears soft contact lenses.

. 7ontraindicated to patients $ho use N/AID/ simultaneously.

6. 7ontraindicated to patients $ho ha%e a history of gastrointestinal bleeding or peptic ulcer.

&. 7ontraindicated to patients $ho are suspected or confirmed cerebro%ascular bleeding.

Ad,erse Effecs:

1. ;espiratory rhinitis, hemoptysis, dyspnea

!. 5I 5I pain, diarrhea, %omiting, nausea

(. 7N/ di<<iness, fatigue, insomnia, headache

. =ematologic neutropenia, leu3openia, decreased =gb or =ct, bone marro$ depression

6. Dermatologic s$eating, dry mucous membrane, pruritus

N&rsin' Res%!nsiiliies:

1. 'onitor 4# upon administration. > ?"@" ne%er administer. ;efer to the doctor.

!. #atients $ho ha%e asthma, aspirin-induced allergy, and nasal polyps are at increased ris3

for de%eloping hypersensiti%ity reactions. Assess for rhinitis, asthma, and urticaria.

(. Assess pain 9note type, location, and intensity: prior to and 1-! hr follo$ingadministration.

. Ketorolac therapy should al$ays be gi%en initially by the I' or I) route. Oral therapy

should be used only as a continuation of parenteral therapy.

6. 7aution patient to a%oid concurrent use of alcohol, aspirin, N/AIDs, acetaminophen, or

other OT7 medications $ithout consulting health care professional.

&. Ad%ise patient to consult if rash, itching, %isual disturbances, tinnitus, $eight gain,edema, blac3 stools, persistent headche, or influen<a-li3e syndromes 9chills,fe%er,muscles

aches, pain: occur.. Bffecti%eness of therapy can be demonstrated by decrease in se%erity of pain. #atients

$ho do not respond to one N/AIDs may respond to another.